Navigation Links
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
Date:8/12/2014

ROCKVILLE, Md., Aug. 12, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.

Synthetic Biologics' academic collaborator, Jennifer Maynard, Ph.D., of The University of Texas at Austin's McKetta Department of Chemical Engineering will present Synthetic Biologics' SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis in an oral presentation scheduled for Sunday, September 7, at 9:45am Eastern Time in Room 209A as part of the "Neonatal Infections and the Case for Maternal Immunization" session.

Title: Rational Design of Antibody Cocktails to Treat Disease Caused by Bordetellae
Authors: M. Kaleko1, A. Nguyen2, E. Wagner2, J. Laber2, L. Goodfield3, W. Smallridge3, E. T. Harvill3, R. F. Wolf4, J. C. Papin4, J. A. Maynard2

"We are pleased to have Dr. Maynard showcase the research supporting the clinical development of SYN-005 amongst esteemed academic peers, and the infectious disease field's foremost leaders at ICAAC, a conference with high academic standards and commitment to providing an overview of the state of infection control and prevention on a global scale," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "This scientific presentation is timely, as we continue to advance our innovative Pertussis program toward clinical-stage development in early 2015."

1Synthetic Biologics, Rockville, MD, 2Universty of Texas at Austin, Austin, TX, 3Penn State Univ., University Park, PA, 4Univ. of Oklahoma Hlth. Sci. Ctr., Oklahoma City, OK

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding Synthetic Biologics' continued advancement of its Pertussis program toward clinical-stage development. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, the additional clinical studies and results not meeting expectations and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):